Thanks KB!See Boffin’s post which is his conjecture that the results were for RC220 and then DT replied that there would be variance. Hence my follow-up questions. Obviously KB’s reference to DT’s previous post also supports the hypothesis of RC220 being used in preclinical work. If all this is correct, then per my post, this is a good validation for us SHs regarding RC220’s efficacy being similar to RC110. (AIMO!)
DT hasn’t refuted this yet… let’s wait and watch.
Ann: Bisantrene shows potent anticancer activity in AML models, page-35
-
- There are more pages in this discussion • 55 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.79%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.54 | $1.56 | $1.53 | $130.2K | 84.73K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 4993 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.58 | 10451 | 1 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |